COMMUNIQUÉS West-GlobeNewswire

Galecto Reports Third Quarter 2024 Financial Results

01/11/2024 - 13:30

- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge [...]

Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial

01/11/2024 - 13:30

DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

01/11/2024 - 13:13

Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic [...]

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

01/11/2024 - 13:06

Conference call to be held Monday, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4 [...]

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

01/11/2024 - 13:00

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

The MUHC Foundation and the Beat 92.5’s Raise Craze raises $95,000 to help strike out breast cancer

01/11/2024 - 13:00

All funds are supporting breast cancer care at the McGill University Health Centre (MUHC) MONTREAL, Nov. 01, 2024 (GLOBE NEWSWIRE) -- The MUHC Foundation, in collaboration with The Beat 92.5 and Pink in the City, raised [...]

L’événement Raise Craze de la Fondation du CUSM et de The Beat 92.5 recueille 95 000 $ pour aider à combattre le cancer du sein

01/11/2024 - 13:00

Tous les fonds appuient les soins du cancer du sein au Centre universitaire de santé McGill (CUSM) MONTRÉAL, 01 nov. 2024 (GLOBE NEWSWIRE) -- La Fondation du CUSM, en collaboration avec The Beat 92.5 et Pink in the City [...]

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01/11/2024 - 13:00

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

01/11/2024 - 13:00

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/11/2024 - 12:30

CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]

Entourage Health Provides Company Update

01/11/2024 - 12:00

TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) ("Entourage" or the "Company") , a Canadian producer and distributor of award-winning cannabis products, announced [...]

Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results

01/11/2024 - 12:00

Reports record third quarter 2024 revenue of $7.6 million , representing growth of 24% compared to the third quarter of 2023 Placed seven Growth Direct ® systems in the third quarter of 2024, marking the highest number [...]

Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients

01/11/2024 - 12:00

Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, [...]

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

01/11/2024 - 12:00

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals TNX-801, has [...]

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

01/11/2024 - 12:00

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. [...]

Humber River Health Exceeds Provincial and National Benchmarks in Patient Safety

01/11/2024 - 12:00

TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Humber River Health (Humber) has outperformed provincial and national benchmarks in patient safety, according to the latest Hospital Harm results released by the Canadian [...]

Skye Bioscience to Announce Third Quarter 2024 Results

01/11/2024 - 12:00

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced [...]

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

01/11/2024 - 12:00

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases [...]

Biodesix Announces Third Quarter 2024 Results and Highlights

01/11/2024 - 11:00

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m [...]